Moreover, this chimeric version of the inhibitor is more potent than the original compound and, notably, it also exerts antitumoral effects on cells with secondary resistance to classical drugs used in the HER2-positive breast cancer clinic. The gene discussed is ERBB2; the disease is breast carcinoma.